European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Identifieur interne : 001643 ( Main/Exploration ); précédent : 001642; suivant : 001644European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Auteurs : M. Mosca [Italie] ; C. Tani [Italie] ; M. Aringer [Allemagne] ; S. Bombardieri [Italie] ; D. Boumpas [Grèce] ; R. Brey [États-Unis] ; R. Cervera [Espagne] ; A. Doria [Italie] ; D. Jayne [Royaume-Uni] ; M A Khamashta [Royaume-Uni] ; A. Kuhn [Allemagne] ; C. Gordon [Royaume-Uni] ; M. Petri [États-Unis] ; O P Rekvig [Norvège] ; M. Schneider [Allemagne] ; Y. Sherer [Israël] ; Y. Shoenfeld [Israël] ; J S Smolen [Autriche] ; R. Talarico [Italie] ; A. Tincani [Italie] ; R F Van Vollenhoven [Suède] ; M M Ward [États-Unis] ; V P Werth [États-Unis] ; L. Carmona [Espagne]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2010-07.
English descriptors
- Teeft :
- Active disease, American academy, Antimalarial drugs, Antiphospholipid antibodies, Ares, Arthritis, Arthritis rheum, Autoimmune diseases, Blood pressure, Bone mineral density, Cancer screening, Cardiovascular, Cardiovascular disease, Cardiovascular risk factors, Clinical practice, Cognitive impairment, Cutaneous, Cutaneous lupus disease area, Damage development, Delphi surveys, Diffuse proliferative lupus glomerulonephritis, Disease activity, Disease control, Disease progression, Erythematosus, Eular, European league, Further testing, General population, Glucocorticoid, Guideline, High dose glucocorticoids, High risk, Immunosuppressive drugs, Immunosuppressive therapy, Inactive disease, Kidney biopsy, Laboratory assessment, Lupus, Lupus erythematosus, Lupus nephritis, Lupus patients, Monitoring patients, Observational studies, Organ damage, Organ involvement, Oxford centre, Patient assessment, Predictive value, Premature atherosclerosis, Preventive measures, Protective antibodies, Recommendations table, Renal, Renal disease, Rheum, Rheumatic diseases, Rheumatol, Rheumatology, Risk factors, Serum creatinine, Severity index, Small group discussion, Standardised core, Supplementary material, Systematic literature review, Systemic, Systemic lupus erythematosus, Task force, Urine microscopy, Urine ratio, Vaccination, Visual analogue scale, Worse prognosis.
Abstract
Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.
Url:
DOI: 10.1136/ard.2009.117200
Affiliations:
- Allemagne, Autriche, Espagne, Grèce, Israël, Italie, Norvège, Royaume-Uni, Suède, États-Unis
- Angleterre, Communauté de Madrid, District de Dresde, Grand Londres, Maryland, Midlands de l'Ouest, Pennsylvanie, Saxe (Land), Svealand, Texas, Toscane
- Birmingham, Dresde, Londres, Madrid, Pise, Stockholm
- Université de Birmingham, Université de Pise
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000716
- to stream Istex, to step Curation: 000716
- to stream Istex, to step Checkpoint: 000588
- to stream Main, to step Merge: 001646
- to stream Main, to step Curation: 001643
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title><author><name sortKey="Mosca, M" sort="Mosca, M" uniqKey="Mosca M" first="M" last="Mosca">M. Mosca</name></author><author><name sortKey="Tani, C" sort="Tani, C" uniqKey="Tani C" first="C" last="Tani">C. Tani</name></author><author><name sortKey="Aringer, M" sort="Aringer, M" uniqKey="Aringer M" first="M" last="Aringer">M. Aringer</name></author><author><name sortKey="Bombardieri, S" sort="Bombardieri, S" uniqKey="Bombardieri S" first="S" last="Bombardieri">S. Bombardieri</name></author><author><name sortKey="Boumpas, D" sort="Boumpas, D" uniqKey="Boumpas D" first="D" last="Boumpas">D. Boumpas</name></author><author><name sortKey="Brey, R" sort="Brey, R" uniqKey="Brey R" first="R" last="Brey">R. Brey</name></author><author><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R" last="Cervera">R. Cervera</name></author><author><name sortKey="Doria, A" sort="Doria, A" uniqKey="Doria A" first="A" last="Doria">A. Doria</name></author><author><name sortKey="Jayne, D" sort="Jayne, D" uniqKey="Jayne D" first="D" last="Jayne">D. Jayne</name></author><author><name sortKey="Khamashta, M A" sort="Khamashta, M A" uniqKey="Khamashta M" first="M A" last="Khamashta">M A Khamashta</name></author><author><name sortKey="Kuhn, A" sort="Kuhn, A" uniqKey="Kuhn A" first="A" last="Kuhn">A. Kuhn</name></author><author><name sortKey="Gordon, C" sort="Gordon, C" uniqKey="Gordon C" first="C" last="Gordon">C. Gordon</name></author><author><name sortKey="Petri, M" sort="Petri, M" uniqKey="Petri M" first="M" last="Petri">M. Petri</name></author><author><name sortKey="Rekvig, O P" sort="Rekvig, O P" uniqKey="Rekvig O" first="O P" last="Rekvig">O P Rekvig</name></author><author><name sortKey="Schneider, M" sort="Schneider, M" uniqKey="Schneider M" first="M" last="Schneider">M. Schneider</name></author><author><name sortKey="Sherer, Y" sort="Sherer, Y" uniqKey="Sherer Y" first="Y" last="Sherer">Y. Sherer</name></author><author><name sortKey="Shoenfeld, Y" sort="Shoenfeld, Y" uniqKey="Shoenfeld Y" first="Y" last="Shoenfeld">Y. Shoenfeld</name></author><author><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name></author><author><name sortKey="Talarico, R" sort="Talarico, R" uniqKey="Talarico R" first="R" last="Talarico">R. Talarico</name></author><author><name sortKey="Tincani, A" sort="Tincani, A" uniqKey="Tincani A" first="A" last="Tincani">A. Tincani</name></author><author><name sortKey="Van Vollenhoven, R F" sort="Van Vollenhoven, R F" uniqKey="Van Vollenhoven R" first="R F" last="Van Vollenhoven">R F Van Vollenhoven</name></author><author><name sortKey="Ward, M M" sort="Ward, M M" uniqKey="Ward M" first="M M" last="Ward">M M Ward</name></author><author><name sortKey="Werth, V P" sort="Werth, V P" uniqKey="Werth V" first="V P" last="Werth">V P Werth</name></author><author><name sortKey="Carmona, L" sort="Carmona, L" uniqKey="Carmona L" first="L" last="Carmona">L. Carmona</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2543BEBD79DA58FAB1F39011EBF93221EDEADD0F</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1136/ard.2009.117200</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-7WSDNB4K-T/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000716</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000716</idno><idno type="wicri:Area/Istex/Curation">000716</idno><idno type="wicri:Area/Istex/Checkpoint">000588</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000588</idno><idno type="wicri:doubleKey">0003-4967:2010:Mosca M:european:league:against</idno><idno type="wicri:Area/Main/Merge">001646</idno><idno type="wicri:Area/Main/Curation">001643</idno><idno type="wicri:Area/Main/Exploration">001643</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</title><author><name sortKey="Mosca, M" sort="Mosca, M" uniqKey="Mosca M" first="M" last="Mosca">M. Mosca</name><affiliation wicri:level="4"><country xml:lang="fr">Italie</country><wicri:regionArea>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Tani, C" sort="Tani, C" uniqKey="Tani C" first="C" last="Tani">C. Tani</name><affiliation wicri:level="4"><country xml:lang="fr">Italie</country><wicri:regionArea>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Aringer, M" sort="Aringer, M" uniqKey="Aringer M" first="M" last="Aringer">M. Aringer</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>University Clinical Center Carl Gustav Carus at the Technical University of Dresden, Dresden</wicri:regionArea><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Bombardieri, S" sort="Bombardieri, S" uniqKey="Bombardieri S" first="S" last="Bombardieri">S. Bombardieri</name><affiliation wicri:level="4"><country xml:lang="fr">Italie</country><wicri:regionArea>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Boumpas, D" sort="Boumpas, D" uniqKey="Boumpas D" first="D" last="Boumpas">D. Boumpas</name><affiliation wicri:level="1"><country xml:lang="fr">Grèce</country><wicri:regionArea>University of Crete Medical School, Heraklion, Crete</wicri:regionArea><wicri:noRegion>Crete</wicri:noRegion></affiliation></author><author><name sortKey="Brey, R" sort="Brey, R" uniqKey="Brey R" first="R" last="Brey">R. Brey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine/Neurology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R" last="Cervera">R. Cervera</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia</wicri:regionArea><wicri:noRegion>Catalonia</wicri:noRegion></affiliation></author><author><name sortKey="Doria, A" sort="Doria, A" uniqKey="Doria A" first="A" last="Doria">A. Doria</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Rheumatology, University of Padova, Padova</wicri:regionArea><wicri:noRegion>Padova</wicri:noRegion></affiliation></author><author><name sortKey="Jayne, D" sort="Jayne, D" uniqKey="Jayne D" first="D" last="Jayne">D. Jayne</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Renal Unit, Addenbrooke's Hospital, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Khamashta, M A" sort="Khamashta, M A" uniqKey="Khamashta M" first="M A" last="Khamashta">M A Khamashta</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Lupus Research Unit, Rayne Institute, St Thomas Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Kuhn, A" sort="Kuhn, A" uniqKey="Kuhn A" first="A" last="Kuhn">A. Kuhn</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University of Muenster, Muenster</wicri:regionArea><wicri:noRegion>Muenster</wicri:noRegion><wicri:noRegion>Muenster</wicri:noRegion></affiliation></author><author><name sortKey="Gordon, C" sort="Gordon, C" uniqKey="Gordon C" first="C" last="Gordon">C. Gordon</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>School of Immunity & Infection, University of Birmingham, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName><orgName type="university">Université de Birmingham</orgName></affiliation></author><author><name sortKey="Petri, M" sort="Petri, M" uniqKey="Petri M" first="M" last="Petri">M. Petri</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Rekvig, O P" sort="Rekvig, O P" uniqKey="Rekvig O" first="O P" last="Rekvig">O P Rekvig</name><affiliation wicri:level="1"><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Biochemistry, Institute of Medical Biology, Medical Faculty, University of Tromsø, Tromsø</wicri:regionArea><wicri:noRegion>Tromsø</wicri:noRegion></affiliation></author><author><name sortKey="Schneider, M" sort="Schneider, M" uniqKey="Schneider M" first="M" last="Schneider">M. Schneider</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Rheumatology, Clinic of Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf</wicri:regionArea><wicri:noRegion>Duesseldorf</wicri:noRegion><wicri:noRegion>Duesseldorf</wicri:noRegion></affiliation></author><author><name sortKey="Sherer, Y" sort="Sherer, Y" uniqKey="Sherer Y" first="Y" last="Sherer">Y. Sherer</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Hospital Management, Tel-Aviv Sourasky Medical Center, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Shoenfeld, Y" sort="Shoenfeld, Y" uniqKey="Shoenfeld Y" first="Y" last="Shoenfeld">Y. Shoenfeld</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Medicine B and Center of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Rheumatology, Medical University of Vienna</wicri:regionArea><wicri:noRegion>Medical University of Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Talarico, R" sort="Talarico, R" uniqKey="Talarico R" first="R" last="Talarico">R. Talarico</name><affiliation wicri:level="4"><country xml:lang="fr">Italie</country><wicri:regionArea>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa</wicri:regionArea><placeName><settlement type="city">Pise</settlement><region nuts="2">Toscane</region></placeName><orgName type="university">Université de Pise</orgName></affiliation></author><author><name sortKey="Tincani, A" sort="Tincani, A" uniqKey="Tincani A" first="A" last="Tincani">A. Tincani</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>UO Reumatologia e Immunologia Clinica, Spedali Civili e Università, Brescia</wicri:regionArea><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="Van Vollenhoven, R F" sort="Van Vollenhoven, R F" uniqKey="Van Vollenhoven R" first="R F" last="Van Vollenhoven">R F Van Vollenhoven</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>The Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Ward, M M" sort="Ward, M M" uniqKey="Ward M" first="M M" last="Ward">M M Ward</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, US Department of Health and Human Services, Bethesda, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Werth, V P" sort="Werth, V P" uniqKey="Werth V" first="V P" last="Werth">V P Werth</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Carmona, L" sort="Carmona, L" uniqKey="Carmona L" first="L" last="Carmona">L. Carmona</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Research Unit, Sociedad Española de Reumatología, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2010-07">2010-07</date><biblScope unit="volume">69</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1269">1269</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active disease</term><term>American academy</term><term>Antimalarial drugs</term><term>Antiphospholipid antibodies</term><term>Ares</term><term>Arthritis</term><term>Arthritis rheum</term><term>Autoimmune diseases</term><term>Blood pressure</term><term>Bone mineral density</term><term>Cancer screening</term><term>Cardiovascular</term><term>Cardiovascular disease</term><term>Cardiovascular risk factors</term><term>Clinical practice</term><term>Cognitive impairment</term><term>Cutaneous</term><term>Cutaneous lupus disease area</term><term>Damage development</term><term>Delphi surveys</term><term>Diffuse proliferative lupus glomerulonephritis</term><term>Disease activity</term><term>Disease control</term><term>Disease progression</term><term>Erythematosus</term><term>Eular</term><term>European league</term><term>Further testing</term><term>General population</term><term>Glucocorticoid</term><term>Guideline</term><term>High dose glucocorticoids</term><term>High risk</term><term>Immunosuppressive drugs</term><term>Immunosuppressive therapy</term><term>Inactive disease</term><term>Kidney biopsy</term><term>Laboratory assessment</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus nephritis</term><term>Lupus patients</term><term>Monitoring patients</term><term>Observational studies</term><term>Organ damage</term><term>Organ involvement</term><term>Oxford centre</term><term>Patient assessment</term><term>Predictive value</term><term>Premature atherosclerosis</term><term>Preventive measures</term><term>Protective antibodies</term><term>Recommendations table</term><term>Renal</term><term>Renal disease</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatol</term><term>Rheumatology</term><term>Risk factors</term><term>Serum creatinine</term><term>Severity index</term><term>Small group discussion</term><term>Standardised core</term><term>Supplementary material</term><term>Systematic literature review</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Task force</term><term>Urine microscopy</term><term>Urine ratio</term><term>Vaccination</term><term>Visual analogue scale</term><term>Worse prognosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objectives To develop recommendations for monitoring patients with systemic lupus erythematosus (SLE) in clinical practice and observational studies and to develop a standardised core set of variables to monitor SLE. Methods We followed the European League Against Rheumatism (EULAR) standardised procedures for guideline development. The following techniques were applied: nominal groups, Delphi surveys for prioritisation, small group discussion, systematic literature review and two Delphi rounds to obtain agreement. The panel included rheumatologists, internists, dermatologists, a nephrologist and an expert related to national research agencies. The level of evidence and grading of recommendations were determined according to the Levels of Evidence and Grades of Recommendations of the Oxford Centre for Evidence-Based Medicine. Results A total of 10 recommendations have been developed, covering the following aspects: patient assessment, cardiovascular risk factors, other risk factors (osteoporosis, cancer), infection risk (screening, vaccination, monitoring), frequency of assessments, laboratory tests, mucocutaneous involvement, kidney monitoring, neuropsychological manifestations and ophthalmology assessment. A ‘core set’ of minimal variables for the assessment and monitoring of patients with SLE in clinical practice was developed that included some of the recommendations. In addition to the recommendations, indications for specific organ assessments that were viewed as part of good clinical practice were discussed and included in the flow chart. Conclusions A set of recommendations for monitoring patients with SLE in routine clinical practice has been developed. The use of a standardised core set to monitor patients with SLE should facilitate clinical practice, as well as the quality control of care for patients with SLE, and the collection and comparison of data in observational studies.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>Espagne</li><li>Grèce</li><li>Israël</li><li>Italie</li><li>Norvège</li><li>Royaume-Uni</li><li>Suède</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Communauté de Madrid</li><li>District de Dresde</li><li>Grand Londres</li><li>Maryland</li><li>Midlands de l'Ouest</li><li>Pennsylvanie</li><li>Saxe (Land)</li><li>Svealand</li><li>Texas</li><li>Toscane</li></region><settlement><li>Birmingham</li><li>Dresde</li><li>Londres</li><li>Madrid</li><li>Pise</li><li>Stockholm</li></settlement><orgName><li>Université de Birmingham</li><li>Université de Pise</li></orgName></list><tree><country name="Italie"><region name="Toscane"><name sortKey="Mosca, M" sort="Mosca, M" uniqKey="Mosca M" first="M" last="Mosca">M. Mosca</name></region><name sortKey="Bombardieri, S" sort="Bombardieri, S" uniqKey="Bombardieri S" first="S" last="Bombardieri">S. Bombardieri</name><name sortKey="Doria, A" sort="Doria, A" uniqKey="Doria A" first="A" last="Doria">A. Doria</name><name sortKey="Talarico, R" sort="Talarico, R" uniqKey="Talarico R" first="R" last="Talarico">R. Talarico</name><name sortKey="Tani, C" sort="Tani, C" uniqKey="Tani C" first="C" last="Tani">C. Tani</name><name sortKey="Tincani, A" sort="Tincani, A" uniqKey="Tincani A" first="A" last="Tincani">A. Tincani</name></country><country name="Allemagne"><region name="Saxe (Land)"><name sortKey="Aringer, M" sort="Aringer, M" uniqKey="Aringer M" first="M" last="Aringer">M. Aringer</name></region><name sortKey="Kuhn, A" sort="Kuhn, A" uniqKey="Kuhn A" first="A" last="Kuhn">A. Kuhn</name><name sortKey="Schneider, M" sort="Schneider, M" uniqKey="Schneider M" first="M" last="Schneider">M. Schneider</name></country><country name="Grèce"><noRegion><name sortKey="Boumpas, D" sort="Boumpas, D" uniqKey="Boumpas D" first="D" last="Boumpas">D. Boumpas</name></noRegion></country><country name="États-Unis"><region name="Texas"><name sortKey="Brey, R" sort="Brey, R" uniqKey="Brey R" first="R" last="Brey">R. Brey</name></region><name sortKey="Petri, M" sort="Petri, M" uniqKey="Petri M" first="M" last="Petri">M. Petri</name><name sortKey="Ward, M M" sort="Ward, M M" uniqKey="Ward M" first="M M" last="Ward">M M Ward</name><name sortKey="Werth, V P" sort="Werth, V P" uniqKey="Werth V" first="V P" last="Werth">V P Werth</name></country><country name="Espagne"><noRegion><name sortKey="Cervera, R" sort="Cervera, R" uniqKey="Cervera R" first="R" last="Cervera">R. Cervera</name></noRegion><name sortKey="Carmona, L" sort="Carmona, L" uniqKey="Carmona L" first="L" last="Carmona">L. Carmona</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Jayne, D" sort="Jayne, D" uniqKey="Jayne D" first="D" last="Jayne">D. Jayne</name></noRegion><name sortKey="Gordon, C" sort="Gordon, C" uniqKey="Gordon C" first="C" last="Gordon">C. Gordon</name><name sortKey="Khamashta, M A" sort="Khamashta, M A" uniqKey="Khamashta M" first="M A" last="Khamashta">M A Khamashta</name></country><country name="Norvège"><noRegion><name sortKey="Rekvig, O P" sort="Rekvig, O P" uniqKey="Rekvig O" first="O P" last="Rekvig">O P Rekvig</name></noRegion></country><country name="Israël"><noRegion><name sortKey="Sherer, Y" sort="Sherer, Y" uniqKey="Sherer Y" first="Y" last="Sherer">Y. Sherer</name></noRegion><name sortKey="Shoenfeld, Y" sort="Shoenfeld, Y" uniqKey="Shoenfeld Y" first="Y" last="Shoenfeld">Y. Shoenfeld</name></country><country name="Autriche"><noRegion><name sortKey="Smolen, J S" sort="Smolen, J S" uniqKey="Smolen J" first="J S" last="Smolen">J S Smolen</name></noRegion></country><country name="Suède"><region name="Svealand"><name sortKey="Van Vollenhoven, R F" sort="Van Vollenhoven, R F" uniqKey="Van Vollenhoven R" first="R F" last="Van Vollenhoven">R F Van Vollenhoven</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001643 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001643 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2543BEBD79DA58FAB1F39011EBF93221EDEADD0F
|texte= European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
}}
| This area was generated with Dilib version V0.6.33. |  |